[Previous Months][Date Index][Thread Index][Join - Register][Login]
  [Message Prev][Message Next][Thread Prev][Thread Next]

[IP] New Drug Holds Promise As Once-Daily Diabetes Therapy



http://www.diabetesincontrol.com/issue118/item11.shtml

New Drug Holds Promise As Once-Daily Diabetes Therapy
It caused an increase in insulin secretion rate, suppression of glucagon 
secretion and a delay in gastric emptying.



NN2211, an investigational drug has a pharmacokinetic profile indicating it 
may offer another option for once-daily treatment of diabetes, especially 
type 2 diabetes, European investigators report in the August issue of 
Diabetes Care.

NN2211 is a long-acting glucagon-like peptide 1 derivative, lead 
investigator Dr. Bodil Elbr nd of Novo Nordisk, Bagsvaerd, Denmark, and 
colleagues report. The researchers enrolled 72 healthy adult male volunteers 
in a randomized, placebo-controlled dose-escalating study of NN2211.

Eight consecutive dose schedules, ranging from 1.25 to 20 g /kg, were 
analyzed. In each dose group, three of eight subjects underwent intravenous 
glucose tolerance testing 9 hours after drug administration. The drug was 
administered subcutaneously, and 24-hour glucose, insulin and glucagon 
profiles were assessed in the subjects.

Dr. Elbr nd group notes that the half-life of NN2211 was 11 to 15 hours. 
NN2211 showed "borderline-significant " lowering of glucose levels compared 
with placebo. In patients who underwent glucose tolerance testing, there was 
a statistically significant increase in insulin secretion but no significant 
effect on glucagon levels.

The investigators point out that "the observed stimulation of insulin 
secretion was clearly dose-related (in contrast to the glucose increase)." 
They also note that "NN2211 was found to reduce fasting and post-prandial 
glycemia."

"This effect was found to be mediated via an increase in insulin secretion 
rate, suppression of glucagon secretion and a delay in gastric emptying," 
Dr. Elbr nd's team writes.

The primary adverse events reported by patients were headache, dizziness, 
nausea and vomiting. The researchers suggest that the latter two symptoms 
are likely related to the delayed gastric emptying induced by NN2211.  
Diabetes Care 2002;25:1398-1404.








_________________________________________________________________
Join the worlds largest e-mail service with MSN Hotmail. 
http://www.hotmail.com
----------------------------------------------------------
for HELP or to subscribe/unsubscribe, contact: HELP@insulin-pumpers.org
send a DONATION http://www.Insulin-Pumpers.org/donate.shtml